BR0317567A - Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação - Google Patents
Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparaçãoInfo
- Publication number
- BR0317567A BR0317567A BR0317567-7A BR0317567A BR0317567A BR 0317567 A BR0317567 A BR 0317567A BR 0317567 A BR0317567 A BR 0317567A BR 0317567 A BR0317567 A BR 0317567A
- Authority
- BR
- Brazil
- Prior art keywords
- tamsulosin
- pharmaceutical composition
- controlled release
- preparation
- release pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1292DE2002 IN192381B (OSRAM) | 2002-12-20 | 2002-12-20 | |
| PCT/IB2003/006072 WO2004056354A1 (en) | 2002-12-20 | 2003-12-18 | Controlled release pharmaceutical compositions of tamsulosin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317567A true BR0317567A (pt) | 2005-11-22 |
Family
ID=32676755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317567-7A BR0317567A (pt) | 2002-12-20 | 2003-12-18 | Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1596849A1 (OSRAM) |
| JP (1) | JP2006512358A (OSRAM) |
| CN (1) | CN1744889A (OSRAM) |
| AU (1) | AU2003288604A1 (OSRAM) |
| BR (1) | BR0317567A (OSRAM) |
| CA (1) | CA2511208A1 (OSRAM) |
| IN (1) | IN192381B (OSRAM) |
| RU (1) | RU2005121999A (OSRAM) |
| WO (1) | WO2004056354A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004066991A1 (ja) * | 2003-01-27 | 2004-08-12 | Yamanouchi Pharmaceutical Co., Ltd. | タムスロシンまたはその塩の腸溶性徐放微粒子およびその製造法 |
| EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| SI1618873T1 (sl) * | 2004-07-14 | 2007-10-31 | Siegfried Generics Int Ag | Granulat za kontrolirano sproščanje tamsulozina, ki vsebuje alginat |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| WO2007112581A1 (en) | 2006-04-03 | 2007-10-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| EP2010162A4 (en) * | 2006-04-03 | 2013-01-09 | Isa Odidi | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2008089593A1 (fr) * | 2007-01-18 | 2008-07-31 | Standard Chem. & Pharm. Co., Ltd. | Preparation de tamsulosine a liberation prolongee et procede de production associe |
| WO2010001574A1 (ja) * | 2008-07-01 | 2010-01-07 | 沢井製薬株式会社 | タムスロシン塩酸塩を含有する球形微粒子の製造方法 |
| CN101695478B (zh) * | 2009-10-23 | 2012-01-18 | 江苏大学 | 盐酸坦索罗辛缓释微丸制剂及其制备方法 |
| KR101423237B1 (ko) * | 2010-05-04 | 2014-07-30 | 주식회사 삼양바이오팜 | 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제 |
| CN103315962A (zh) * | 2013-02-01 | 2013-09-25 | 北京科信必成医药科技发展有限公司 | 一种坦索罗辛缓释微丸制剂及其制备方法 |
| CN103142492A (zh) * | 2013-02-01 | 2013-06-12 | 北京科信必成医药科技发展有限公司 | 一种缓释微丸制剂及其制备方法 |
| CN103919735B (zh) * | 2014-05-04 | 2018-04-17 | 翰宇药业(武汉)有限公司 | 一种盐酸坦索罗辛缓释微丸及其制备方法 |
| EP2949319A1 (en) | 2014-05-26 | 2015-12-02 | Galenicum Health S.L. | Pharmaceutical compositions comprising an active agent |
| KR20190019061A (ko) * | 2016-05-04 | 2019-02-26 | 아스펜 파크 파마슈티컬스 인코포레이티드 | 지연된 방출 경구 탐술로신 하이드로클로라이드 |
| EP3473244A1 (en) | 2017-10-20 | 2019-04-24 | Veru Inc. | Controlled release oral tamsulosin hydrochloride |
| EP3473245A1 (en) | 2017-10-20 | 2019-04-24 | Veru Inc. | Controlled release oral tamsulosin hydrochloride |
| KR20200078146A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법 |
| WO2025201521A1 (zh) * | 2024-03-29 | 2025-10-02 | 南京三迭纪医药科技有限公司 | 一种调节释放的口服药物剂型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| DK1443917T3 (da) * | 2001-11-07 | 2006-07-17 | Synthon Bv | Tamsulosintabletter |
-
2002
- 2002-12-20 IN IN1292DE2002 patent/IN192381B/en unknown
-
2003
- 2003-12-18 AU AU2003288604A patent/AU2003288604A1/en not_active Abandoned
- 2003-12-18 EP EP03780445A patent/EP1596849A1/en not_active Withdrawn
- 2003-12-18 BR BR0317567-7A patent/BR0317567A/pt not_active Application Discontinuation
- 2003-12-18 JP JP2004561893A patent/JP2006512358A/ja not_active Withdrawn
- 2003-12-18 CA CA002511208A patent/CA2511208A1/en not_active Abandoned
- 2003-12-18 WO PCT/IB2003/006072 patent/WO2004056354A1/en not_active Ceased
- 2003-12-18 RU RU2005121999/15A patent/RU2005121999A/ru not_active Application Discontinuation
- 2003-12-18 CN CNA2003801094133A patent/CN1744889A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2511208A1 (en) | 2004-07-08 |
| CN1744889A (zh) | 2006-03-08 |
| EP1596849A1 (en) | 2005-11-23 |
| WO2004056354A1 (en) | 2004-07-08 |
| AU2003288604A1 (en) | 2004-07-14 |
| JP2006512358A (ja) | 2006-04-13 |
| RU2005121999A (ru) | 2006-01-20 |
| IN192381B (OSRAM) | 2004-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317567A (pt) | Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| BR0213040A (pt) | Composto, processo para preparar um composto, e, método de tratar doenças | |
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| CA2447924A1 (en) | Olopatadine formulations for topical administration | |
| BR0113626A (pt) | Formulações de liberação sustentada para secretores de hormÈnio do crescimento | |
| BR0011116A (pt) | Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| BRPI0412241A (pt) | formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa) | |
| BR0108893A (pt) | Composição farmacêutica, composto e processo de preparação de compostos | |
| PA8559401A1 (es) | Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas. | |
| BRPI0408990A (pt) | derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| BRPI0408655A (pt) | formulações compreendendo um agente ativo e cacau em pó e a sua utilização | |
| BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida | |
| NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
| BR0312728A (pt) | Formulação em tablete dispersìvel e processo para sua preparação | |
| NO20013060L (no) | Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff | |
| IL148874A0 (en) | Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them | |
| NO20070952L (no) | Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike | |
| BR0115989A (pt) | Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| AR046226A1 (es) | Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |